Neurology
ANAVEX2-73 shows encouraging clinical signs for PDD
Anavex has announced preliminary findings from an extended study of its experimental drug ANAVEX2-73 in patients with Parkinson’s Disease Dementia (PDD).
University of Birmingham reports new Phase II trial of exenatide for IIH
Despite recent approvals, significant unmet need remains in Alzheimer’s market
Diabetic neuropathic pain market projected to grow at a CAGR of 6% between 2021-2031
Viz.ai announces partnership to accelerate enrolment in BEACH trial
Tonix Pharmaceuticals begins subject enrolment in migraine therapy trial
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
